
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is well-positioned for growth in the contract research industry thanks to its focus on oncology and metabolic diseases, as well as its use of advanced technologies to improve trial management. However, potential risks such as regulatory changes and delays in clinical trials could impact the company's performance. Investors should closely monitor these potential risks while considering Icon's strong bookings and potential for future buybacks in 2026.
Bears say
Icon is currently facing several challenges, including passthrough volatility, cancellation concerns, and margin compression due to a higher proportion of passthrough services. These challenges have led to uncertainty surrounding reported book-to-bill figures and make it difficult to accurately forecast future financial performance. Additionally, the company may face headwinds if biopharma industries reduce outsourcing to clinical CROs or if there is increased competition for talent, leading to wage inflation and lower margins. These factors, along with potential headwinds from stagnant or reduced R&D spending by biopharma companies, contribute to a negative outlook on Icon's stock.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares